Skip to main content

Table 1 GPR119 endogenous ligands

From: Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease

Name

EC50 (μM)

Refs.

2-Oleoyl glycerol (2-OG)

2.5–17

[44] [121] [61] [62]

Oleoylethanolamide (OEA)

0.2–5

[15, 63]

N-Oleoyl-dopamine (OLDA)

3.2

[53]

Lysophosphatidylethanolamine

5.7

[36]

Lysophosphatidylinositol

5.7

[36]

Lysophosphatidylserine

 > 30

[36]

Lysophosphatidic acid

 > 30

[36]

Sphingosylphosphorylcholine

 > 30

[36]

Oleic acid

 > 1000

[36]

Palmitoyl-lysophosphatidylcholine (16:0-lysoPC)

1.6–2.1

[36]

Stearoyl-lysophosphatidylcholine (18:0-lysoPC)

3.3

[36]

Oleoyl-lysophosphatidylcholine (18:1-lysoPC)

1.5–9

[36]

5-Hydroxy-eicosapentaenoic acid (5-HEPE)

0.03–3

[52]

Palmitoylethanolamide (PEA)

0.84

[61]

Linoleoylethanolamide (LEA)

0.56–5

[61]

2-Linoleoyl glycerol

12

[61]

2-Palmitoyl glycerol

11

[61]

2-Arachidonoyl glycerol

NA

[61]

1-Oleoyl glycerol(1-OG)

2.8

[61]

1-Linoleoyl glycerol

36

[61]

Anandamide

NA

[61]

Oleamide

4.5

[53]

N-Arachidonoyldopamine

NA

[53]

N-Oleoyl-tyrosine

0.7

[53]

Arachidonoyl ethanolamide (AEA)

NA

[51]

  1. NA not applicable